General Practice Doctors in Springfield, MO Accepting Medicare

6 General Practice doctors found. Showing 1 - 6

Dr. Yung H. Hwang, MD. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1450 E. Kearney, Springfield, MO 65803 Phone: 417-831-0200    Fax: 417-831-0203

Waseem Gazale, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 3259 E Sunshine St Ste Aa, Springfield, MO 65804 Phone: 619-504-6362

Dr. Jessica Nicole Snider, D.O. General Practice Medicare: Accepting Medicare Assignments Practice Location: 2055 S Fremont Ave, Suite 1000, Springfield, MO 65804 Phone: 417-820-8099    Fax: 417-820-8093

Dr. Arthur L Trask, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 1630 N Jefferson Ave, Springfield, MO 65803 Phone: 417-837-1504    Fax: 417-837-1545

Dr. Alexander Edmund Underwood, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 2032 E Kearney St Ste 108, Springfield, MO 65803 Phone: 417-832-8678

Bradley Bradshaw, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 1904 S Shady Hill Ln, Springfield, MO 65809 Phone: 417-860-9044

News Archive

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

Boehringer Ingelheim, Priaxon announce collaboration in development of mdm2/p53 inhibitors for cancer

Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. Priaxon is providing its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigate inhibition of protein-protein interactions. p53 is a human tumor suppressor protein.

Rush Midlife Center addresses health needs of women going through perimenopause

Rush has launched an innovative program dedicated to the comprehensive care of women 40 years of age and older.

JAZD & FierceMarkets launch new online healthcare industry marketplace

JAZD, the leader in online B2B directory service platforms, and premier media partner FierceMarkets announced today their new online healthcare industry marketplace – the FierceMarketplace: HealthTech, provides the industry's most comprehensive online supplier and buyer experience. Over the last two months HealthTech provided over 10,000 unique healthcare professionals with the solutions to their research and decision-making needs.

Xenex Healthcare Services announces commercial launch of pulsed xenon room disinfection system

Xenex Healthcare Services LLC, which specializes in developing disinfection technology for healthcare facilities, today announced the commercial launch of its pulsed xenon room disinfection system and the conclusion of the Xenex system's successful trial at a leading U.S. cancer center. The Xenex system, which is now available, is the fastest, safest, and most effective method for the advanced cleaning of hospital rooms in the world today, quickly destroying all major classes of microorganisms (including viruses, bacteria and bacterial spores) without contact or chemicals.

Read more Medical News

› Verified 6 days ago